š¼ Performance Overview
Boston Scientific reported 22.40% YoY revenue growth, fueled by strong demand in Cardiovascular (+28.80%) and MedSurg (+12.40%) segments. The company achieved a 14.80% operating margin, reflecting stable operational performance despite increased expenses.
š Key Financial Metrics (YoY Growth)
ā« Revenue: $4.56B vs. $3.73B (+22.40%)
ā« Net Income: $566.00M vs. $504.00M (+12.30%)
ā« Adj. EPS: $0.70 vs. $0.55 (+27.27%)
ā« Gross Margin: 67.85% (-0.73pp)
ā« Operating Margin: 14.80% (-0.30pp)
š Segment Breakdown
ā« Cardiovascular: $2.94B (+28.80%)
ā« MedSurg: $1.62B (+12.40%)
š Future Outlook
ā« FY 2025 Revenue Guidance: $18.84B - $19.16B (+12.50% to +14.50% YoY)
ā« FY 2025 Adj. EPS Guidance: $2.80 - $2.87
ā« Strategic Focus: Expansion in cardiovascular solutions, digital innovation, and global market penetration.
š Key Takeaway: Boston Scientific delivered one of its best years, driven by product innovation and strong global demand.